Cargando…
Phase 1 study of TRU-015, a CD20-directed small modular immunopharmaceutical (SMIP™) protein therapeutic, in subjects with rheumatoid arthritis
Autores principales: | Burge, DJ, Bookbinder, SA, Kivitz, AJ, Fleischmann, RM, Shu, C, Bannink, J, Barone, D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061957/ http://dx.doi.org/10.1186/ar2257 |
Ejemplares similares
-
TRU-015, a small modular immunopharmaceutical (SMIP™) drug candidate directed against CD20, demonstrates clinical improvement in subjects with rheumatoid arthritis
por: Burge, DJ, et al.
Publicado: (2007) -
Distinct in vitro binding properties of the anti-CD20 small modular immunopharmaceutical 2LM20-4 result in profound and sustained in vivo potency in cynomolgus monkeys
por: Nickerson-Nutter, Cheryl, et al.
Publicado: (2011) -
CASSIS and SMIPS: promoter-based prediction of secondary metabolite gene clusters in eukaryotic genomes
por: Wolf, Thomas, et al.
Publicado: (2016) -
Targeting PELP1 oncogenic signaling in TNBC with the small molecule inhibitor SMIP34
por: Altwegg, Kristin A., et al.
Publicado: (2023) -
SMIP-30, a potent and selective PPM1A inhibitor with potential to treat tuberculosis
por: Xu, Shujing, et al.
Publicado: (2022)